Speech-Language Pathologists in Steilacoom, WA Accepting Medicare

1 Speech-Language Pathologists found. Showing 1 - 1

Linda Taggart-ross, MSPA CCC-SP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1201 Galloway St, Steilacoom, WA 98388 Phone: 253-983-2568

News Archive

First genetically engineered rat derived from rat ES cells developed with StemCells' technology

StemCells, Inc. announced today that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem (ES) cells. This breakthrough, published this month in the international peer-reviewed journal Nature, opens the door to the types of genetic manipulations previously only possible in mice, and paves the way for modeling a broader range of human diseases with the rat.

Enrollment at U.S. medical schools to reach 30% increase by 2016

New data released today show that enrollment at U.S. medical schools is on target to reach an increase of 30 percent by 2016, according to the annual Medical School Enrollment Survey conducted by the AAMC (Association of American Medical Colleges) Center for Workforce Studies.

New and revealing portrait of Yersinia pestis emerges

Yersinia pestis, the causative agent of the "Black Death" or "Bubonic" plague, has been a scourge of human civilization. One of the most virulent bacterial pathogens known, killing nearly 90% of those infected, Y. pestis was responsible for three historic pandemics that shattered whole societies.

Revised Medicaid sterilization policy supports minority women at risk for unintended pregnancies

A revised Medicaid sterilization policy that removes logistical barriers, including a mandatory 30-day waiting period, could potentially honor women's reproductive decisions, reduce the number of unintended pregnancies and save $215 million in public health costs each year, according to researchers at the University of Pittsburgh School of Medicine.

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Salix Pharmaceuticals, Ltd. today announced the presentation of two analyses of data from its Phase 3 pivotal clinical trials, TARGET 1 and 2, demonstrating a 14-day course of XIFAXAN 550 mg (rifaximin) taken three times daily achieved adequate relief of symptoms of non-constipation irritable bowel syndrome (non-C IBS) in a significantly greater proportion of patients compared with placebo.

Read more Medical News

› Verified 3 days ago